Research Library

This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.

While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.

Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.

In addition to their therapeutic potential, cord blood banks raise ethical and regulatory questions, especially in emerging markets in the Arab world. In this article, the authors review cord blood banking in five countries in the region (Jordan, Saudi Arabia, Egypt, Qatar, and the United Arab Emirates) that were selected for their different CB banking policies and initiatives.

Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from the Baker Institute.

Enhancement of American science, technology, engineering, and math education (STEM) at all levels, even early childhood, is a justifiable federal priority.

Analyzing over 2,800 articles from the top journals that include stem cell research in their publications, this study demonstrates the globalization of stem cell science.

Despite the political nature of stem cell research, this area of science continues to flourish in the United States. In 2011, the NIH funded approximately US$1.2 billion in stem cell research — a steady increase from past years — with US$123 million devoted to human embryonic stem cells. According to the ISI Web of Science, more than 4,000 U.S.-authored stem cell publications were produced in 2011, accounting for approximately 38 percent of the world total. Approximately one-quarter of these publications were collaborations with authors from other countries.

In the face of a persistent decline and stagnation in research and development funding, scientists and engineers must devote more time and effort toward keeping the economic and societal value of science in the public and advocate for it to hold a higher standing in the federal budget. Published in vol. 2, issue 1, of The Journal of Science Policy and Governance.

A rise in the average age of biomedical researchers might inhibit research potential and novel projects that could impact biomedicine and the next generation of scientists in the United States.